Cancer immunotherapy in special challenging populations: recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Maria Gonzalez-Cao,1 Teresa Puertolas,2 Mar Riveiro,3 Eva Muñoz-Couselo,4 Carolina Ortiz,4 Roger Paredes,5,6 Daniel Podzamczer,7 Jose Luis Manzano,8 Jose Molto,5,6 Boris Revollo,5,6 Cristina Carrera,9 Lourdes Mateu,5,6 Sara Fancelli,1,10 Enrique Espinosa,11 Bonaventura Clotet,5,6 Javier Martinez-Picado,5,12 Pablo Cerezuela,13 Ainara Soria,14 Ivan Marquez-Rodas,15 Mario Mandala,16 Alfonso Berrocal,17 for the Spanish Melanoma Group (GEM)

ABSTRACT
Cancer immunotherapy based on the use of antibodies targeting the so-called checkpoint inhibitors, such as programmed cell death-1 receptor, its ligand, or CTLA-4, has shown durable clinical benefit and survival improvement in melanoma and other tumors. However, there are some special situations that could be a challenge for clinical management. Persons with chronic infections, such as HIV-1 or viral hepatitis, latent tuberculosis, or a history of solid organ transplantation, could be candidates for cancer immunotherapy, but their management requires a multidisciplinary approach. The Spanish Melanoma Group (GEM) panel in collaboration with experts in virology and immunology from different centers in Spain reviewed the literature and developed evidence-based guidelines for cancer immunotherapy management in patients with chronic infections and immunosuppression. These are the first clinical guidelines for cancer immunotherapy treatment in special challenging populations. Cancer immunotherapy in chronically infected or immunosuppressed patients is feasible but needs a multidisciplinary approach in order to decrease the risk of complications related to the coexistent comorbidities.

INTRODUCTION
Therapy with immune checkpoint inhibitors that block inhibitory receptors of effector lymphocytes mainly programmed cell death-1 (PD-1) and Cytotoxic T-Lymphocyte Antigen 4 (CTLA-4) or their ligand interactions (PD-L1) is now the standard treatment for different types of cancers. However, data on the feasibility of using these therapies in patients with special clinical situations, such as chronic infections or immunosuppression, are scarce. HIV-1 infection, viral hepatitis, and previous solid organ transplantation are common exclusion criteria in most cancer clinical trials due to concerns about potential complications and the arguable balance between expected benefits and risks. Due to the relevant clinical benefit of immune checkpoint blockers in different types of cancer, including melanoma, development of evidence-based guidelines for the management of these patients is relevant. These guidelines are not exclusively focused on melanoma treatment.

METHODS
A multidisciplinary panel of experts in medical oncology, dermatology, immunology and infectious diseases developed these clinical practice guidelines for the management of approved cancer immunotherapy drugs (anti-PD-1/PD-L1 and anti-CTLA-4 antibodies) in ‘special clinical situations’ related to HIV-1 infection, viral hepatitis, tuberculosis (TB) infection and solid organ transplantation. The authors developed the guidelines based on a critical review of literature, including case series, case reports and clinical trials, as well as their own observational data (online supplemental table S1). These guidelines are not intended to be a systematic review of the literature, but rather to develop a recommendation based on judgment of experts. Panelists discussed the final recommendations in a multidisciplinary cancer
conference that was held in Barcelona on January 24, 2020 (https://www.groupgem.es/eventos-2020/). Due to the limitations of the available evidence, the guidelines are non-mandatory recommendations. Levels of evidence and grade of recommendation were classified according to the European Society for Medical Oncology guidelines (https://www.esmo.org/Guidelines/ESMO-Guidelines-Methodology).

**HIV-1 INFECTION**

**Incidence and pathophysiology**

Since the onset of the HIV/AIDS pandemic in 1981, 74.9 million people have contracted HIV. AIDS-related illnesses account for 32 million deaths. In 2018, 37.9 million people were living with HIV (PLHIV) globally, 1.7 million people became newly infected, and 770,000 people died from AIDS-related illnesses (Joint United Nations Programme on HIV and AIDS Fact Sheet 2019). Life expectancy of PLHIV under viral suppressive combination antiretroviral therapy (cART) approaches that of non-infected persons, but the state of chronic inflammation prompts them to a higher risk of cancer and other comorbidities. This is the reason why cancer is now one of the leading causes of death in HIV-infected persons. Patients infected with HIV-1 have been excluded from clinical trials that evaluate cancer immunotherapies, but recently two prospective trials have shown the safety and feasibility of these therapies in PLHIV (online supplemental table S1).5,6 Previously, retrospective series and case reports had suggested similar safety and activity of anti-PD-1/PD-L1 antibodies in PLHIV, compared with uninfected individuals.7-9 Grade 3 adverse events ranged from 0% to 20%, and grade 4 adverse events appeared in less than 1%.5,6 Also, antitumoral activity of anti-PD-1/PD-L1 antibodies in PLHIV was demonstrated, with a disease control rate of 17%–50%.5,6 In the prospective studies, all patients included had undetectable plasma viral load (pVL) under cART. Moreover, throughout the anti-PD-1/PD-L1 treatment, pVL remained undetected and CD4+ and CD8+ T cell counts were stable. Regarding baseline CD4+ T cell counts, most PLHIV on cART recover CD4+ T cell counts, but some individuals with delayed initiation of cART or who have received previous immunosuppressive therapies, such as chemotherapy, never recovered normal CD4+ T cell levels. The clinical trials led by Uldrick et al6 and Gonzalez-Cao et al9 included six patients and one patient, respectively, with baseline CD4+ T cells below 200 cells per mm³, without suffering any complications due to immunotherapy. Interestingly, one subject with a previously treated metastatic non-small cell lung cancer included in the DURVAST trial with baseline CD4+ T cell counts of 164 cells per mm³ had a long-lasting complete response (32+ months).5,10 Case reports also support the safety of treating patients with CD4+ T cell counts lower than 100 cells per mm³.5,11

**Management and monitoring**

Screening of HIV-1 infection previous to administration of immunotherapy is not mandatory, except for patients with AIDS-defining cancers or persons of groups at higher risk of HIV-1 infection, such as sex workers, men who have sex with men, or intravenous drug users (level of evidence III, grade of recommendation A).

HIV-1-infected individuals with tumor types that are candidates for immunotherapy must be considered for cancer treatment (level of evidence III, grade of recommendation A). Pretreatment pVL must be checked. Immunotherapy should be administered when pVL is undetectable (level of evidence III, grade of recommendation A). Patients must continue on cART therapy (level of evidence III, grade of recommendation A). It is not necessary to modify their cART when they start anticancer treatment with PD-1/PD-L1 antibodies if there is an effective viral suppression (level of evidence III, grade of recommendation A). Blips, defined as transitory detectable HIV viral load below 400 copies/mL, are frequent and have no clinical significance, so it is not necessary to modify anti-PD-1/PD-L1 therapy when blips are detected during therapy (level of evidence III, grade of recommendation A). In patients with recent HIV-1 diagnosis, cART should be started prior to treatment with immunotherapy. Anti-PD-1/PD-L1 treatment should be delayed until viral suppression is achieved (level of evidence IV, grade of recommendation C). Viral suppression is generally achieved in most patients after 4 weeks on cART. In cases where anticancer treatment is an emergency, a simultaneous initiation of immunotherapy with cART could be considered, evaluating risk and benefits of every case, although there is no evidence of the safety of this procedure (level of evidence V, grade of recommendation C). For starting anti-PD-1/PD-L1 therapy, pretreatment CD4+ T cell counts should preferably be above 200 cells per mm³ (level of evidence III, grade of recommendation B). Patients with a CD4+ T cells below 100 cells per mm³ have not been included in clinical trials of anti-PD-1/ PD-L1 antibodies. Therefore, while low CD4+ T cell counts are not an absolute contraindication to immunotherapy, careful evaluation of the risk to benefit ratio in these cases should be assessed (level of evidence V, grade of recommendation C) (figure 1).

The preferred anti-PD-1 antibody under this condition would be pembrolizumab due to availability of concordant prospective and retrospective data demonstrating its safety and activity (level of evidence III, grade of recommendation B). Other anti-PD-1 antibodies have been used in this context with good tolerance, such as nivolumab (level of evidence IV, grade of recommendation C). The preferred anti-PD-L1 antibody would be durvalumab because its safety has been demonstrated in one clinical trial (level of evidence III, grade of recommendation B). There are no prospective data on the safety and activity of other checkpoint inhibitors or combinations in PLHIV, but case reports and series of patients treated with ipilimumab or the combination of
ipilimumab plus nivolumab suggest their safety (level of evidence IV, grade of recommendation C). Other clinical trials are ongoing in order to check the safety of other checkpoint inhibitors in PLHIV, but the mechanisms of action of these therapies do not preclude any significant difference in tolerance and activity among the studied antibodies in this population.

Plasma viremia and CD4+ and CD8+ T cell counts must be periodically monitored (every 2 or 3 months) during immunotherapy (level of evidence III, grade of recommendation B). If pVL becomes detectable in several consecutive analyses, drug resistance genotypic testing and/or therapeutic drug monitoring should be considered (figure 1).

**VIRAL HEPATITIS**

**Incidence and pathophysiology**

Worldwide, an estimated 257 million and 71 million people are living with chronic hepatitis B (HBV) and hepatitis C (HCV) viral infection, respectively. It should be kept in mind that the rate of chronic hepatitis B (hepatitis B surface antigen (HBsAg)-positive) is relatively low in most high-income countries (0.5%–2%); however, the percentage of subjects with evidence of resolved HBV infection (HBsAg-negative with anti-HBc-positive) is 15%–20%. Although both viruses share the same ways of transmission and can produce chronic infection, there are multiple differences between HCV and HBV pathophysiology. First, HBV, but not HCV, integrates into the human DNA, so when an immunosuppressed person gets infected, HBV could be reactivated, even in cases with an apparently resolved infection (HBsAg-negative with anti-HBc-positive). Second, the clinical evolution and dynamics of the viral infection are clearly different, suggesting that immune response dynamics are much more complex in HBV infection than in the case of HCV. While HCV infection evolution is predictable, in the case of HBV the clinical evolution is heterogeneous between patients. After HCV infection, some patients develop chronic viremia, and others have a completely resolved infection into the first 6 months after exposure. After this phase, most chronic HCV-infected patients slowly progress to severe liver disease after more than 20 years, with few exceptions. In comparison, HBV infection evolves in a much more heterogeneous and unpredictable way throughout its entire course. In chronic HBV infection, there are different stages with different levels of viral replication, immune response and liver function. Finally, the third important difference between these two viruses is that HCV infection is curable with highly effective oral direct-acting antiviral agents (DAA), but there is no curative therapy for HBV (online supplemental data 1 and table S2).

Treatment with immune checkpoint inhibitors in patients with chronic hepatitis deserves special consideration as it could produce complications due to an impairment in hepatic function in the case of an advanced liver disease, but also due to a reactivation of chronic infections. Feasibility of treatment with anti-PD-1/PD-L1 antibodies in patients with cirrhosis was assessed in clinical trials studying the efficacy of anti-PD-1 for patients with hepatocellular carcinoma (HCC). Most patients with HCC included in phase I/II studies of nivolumab, pembrolizumab or durvalumab had compensated cirrhosis without unexpected drug-related adverse events. Few patients with decompensated cirrhosis have been treated with immunotherapy, but data suggest that treatment is also well tolerated. From an overall perspective, monoclonal antibodies could be considered safe enough even in moderate hepatic insufficiency as liver metabolism is not necessary for clearance.
Concerning the risk of viral reactivation, recent studies have demonstrated a high rate of viral reactivation of HBV when these patients are treated with anti-PD-1 antibodies (online supplemental table S1). The most important study included 114 HBsAg-positive patients treated with an anti-PD-1 antibody for a median time of 18 weeks, showing a reactivation rate of 17%. When patients were simultaneously under treatment with antiviral therapy, the viral reactivation rate decreased to 1.2%.21 Other studies have also demonstrated in viral suppressed HBsAg-negative patients that checkpoint blockade is well tolerated without adverse events, and even immunotherapy was suggested to have some antiviral activity since HBsAg levels declined in most patients.22 A recent publication has also found that treatment with anti-PD-1 antibodies with simultaneous treatment with antiviral drugs is safe and precludes viral reactivation.23 Indeed, general guidelines for immunosuppressed patients recommend antiviral prophylaxis for patients with occult HBV infection (HBsAg-negative, anti-HBc-positive, with detectable HBV DNA),24 although the risk of reactivation is very low,25 26 and that periodic monitoring of alanine aminotransferase levels, HBsAg and HBV DNA should be performed, with antiviral therapy deferred until confirmation of viral reactivation (seroconversion to HBsAg-positive or detectable HBV DNA). The most frequent antiviral drugs used for HBV are nucleoside or nucleotide analogs (NUCs), such as entecavir, tenofovir disoproxil or tenofovir alafenamide. Another consideration to be aware of is the case of development of immune-related adverse events during cancer immunotherapy. Patients treated with high-dose corticosteroids have a moderate risk of HBV reactivation, especially for cases on therapy for more than 4 weeks or when corticosteroids are combined with antitumor necrosis factor (anti-TNF) agents.24

In cases of HCV infection, anti-PD-1/PD-L1 and anti-CTLA-4 antibodies are also safe (online supplemental table S1). There is no viral reactivation, and moreover in some cases there is a decline in viral replication. A clinical trial of tremelimumab, an anti-CTLA-4 antibody, in a cohort of 20 patients with HCC revealed a drop in HCV RNA in 75% of subjects. More recently, the anti-PD-1 antibody nivolumab demonstrated infection transient reductions in HCV RNA in 60 patients with HCC with HCV infection, although none achieved sustained virological suppression.17

In case of HCV infection, treatment with DAA should be based on the risk of progression of liver disease to HCC, according to the grade of liver fibrosis or cirrhosis, and the potential drug interactions.

Management and monitoring

All patients should be screened for hepatitis viral infection before starting immunotherapy (level of evidence III, grade of recommendation B).

Diagnosis of HCV infection is based on the presence of anti-HCV antibodies and HCV RNA in cases tested positive for anti-HCV. In patients who are HCV RNA-positive, it is mandatory to assess the severity of the liver disease using non-invasive markers in order to rule out advanced liver fibrosis or cirrhosis. In case of liver cirrhosis, liver ultrasound is recommended to exclude HCC, as well as gastroscopy in case of signs of portal hypertension (figure 2).

Figure 2 Diagram of clinical management of viral hepatitis-infected patient candidates for immunotherapy. ALT, alanine aminotransferase blood levels; DAA, direct-acting antiviral agents; HBsAg, hepatitis B surface antigen; HBV, hepatitis B virus; HCV, hepatitis C virus; NUCs, nucleoside or nucleotide analogs; PD-1, programmed cell death-1; PD-L1, programmed cell death-1 ligand.
Screening of HBV infection is based on the performance of both HBsAg and anti-HBc. In patients with a resolved HBV infection, there is a potential risk of viral reactivation, especially in rare cases that have an ‘occult HBV infection’ (anti-HBc-positive with detectable HBV DNA). Patients with HBV infection with positive HBsAg or were HBsAg-negative, and anti-HBc-positive with detectable HBV DNA, should be treated with NUCs before starting cancer immunotherapy (level of evidence III, grade of recommendation A). In case of patients with negative HBsAg and undetectable HBV DNA in plasma, but positive anti-HBc, a close monitoring of alanine aminotransferase blood levels (ALT) levels, HBsAg and HBV DNA should be performed every 6 months during cancer immunotherapy (level of evidence III, grade of recommendation B). In case of ALT increment during immunotherapy, the first step should be urgent determination of both HBsAg and HBV DNA. When both are negative, the recommendation will be the same as that recommended for anti-HBc-negative subjects, although NUC prophylactic therapy should be discussed in the case of immune-related adverse events development and a high dose of immune-suppressive drugs is needed (figure 2).

In patients following immunotherapy treatment who have no evidence of previous exposure to HBV and are unvaccinated (HBsAg negative/anti-HBc-negative/anti-HBs-negative), there are no available data on the effectiveness or safety of HBV vaccination, so there is not enough evidence for or against vaccination recommendation. The panel recommends no prophylactic HBV vaccination immunotherapy in persons without high risk of infection.

In patients with HCV diagnosis, DAAs are indicated, delaying anti-PD-1/PD-L1 treatment until viral suppression is achieved (level of evidence III, grade of recommendation B). In cases where anticancer treatment must be started urgently, a simultaneous initiation of treatment with DAA could be considered (level of evidence V, grade of recommendation C) (figure 2).

TB INFECTION
Incidence and pathophysiology
TB is a global health challenge, now the second leading infectious cause of death in the world. Globally, in 2018, the incidence was 10 million people, and approximately 9% are persons living with HIV infection. There were an estimated 1.2 million TB deaths among HIV-negative people and an additional 251,000 deaths among HIV-infected persons. In Europe, the estimated percentage of people infected by TB is around 3% (online supplemental data 2). Preventive therapy with isoniazid for latent TB was introduced 20 years ago. Older studies precluded a fatality rate due to severe hepatotoxicity in 1%–19% of patients, but more recent studies, limiting the chemoprophylaxis to persons under 35 years old, have demonstrated a rate of clinical hepatotoxicity of only 1 case per 1000 persons.

In patients with cancer, TB could be difficult to identify since the most frequent symptoms (cough, night sweats, fever and weight loss) and interstitial infiltrates in the lung are similar to those produced by cancer.

Recent data have suggested that treatment with checkpoint inhibitors could re-activate latent TB, although few cases of TB reactivation by anti-PD-1/PD-L1 antibodies have been reported and the real incidence of reactivations during immunotherapy is unknown (online supplemental table S1). On the other hand, other therapies that are commonly used for toxicity management of checkpoint inhibitors, such as anti-TNF antibodies, have a higher risk of TB reactivation.

Assessment and diagnosis
Mantoux tuberculin skin test (TST) or interferon gamma release assay (IGRA) is recommended before to immune checkpoint blockade administration (level of evidence V, grade of recommendation C). TST is the standard method for determining whether a person is infected with Mycobacterium tuberculosis (MT). However, TST has sensitivity problems, with poor or non-existent response in patients with impaired cellular immunity, and also low specificity, given that some antigens are shared by non-tuberculosis mycobacteria (NTM) and BCG vaccines previously inoculated. IGRA is a blood test that works by measuring the immune response to the TB bacteria. An IGRA test is not reactive to BCG vaccine or most NTM, so IGRA is more sensitive than TST in immunosuppressed individuals, more specific in the BCG vaccinated population, and in people infected with NTM. For patients with cancer, IGRA is preferred over TST. Both techniques demonstrate an immune response to MT antigens, rather than a true infection by the micro-organism. All positive patients must be evaluated to rule out active TB (level of evidence IV, grade of recommendation A). The evaluation includes clinical history, physical examination, and chest X-radiograph (or thoracic CT scan) and respiratory sampling. Patients with relevant clinical manifestations and/or abnormal chest X-radiograph should submit three sputum specimens (obtained via cough or induction at least 8 hours apart and including at least one early morning specimen) for acid-fast bacilli smear, mycobacterial culture, and nucleic acid amplification testing. Of these tests, the more sensitive are the molecular techniques that analyze the nucleic acid amplification, such as Xpert MTB/RIF or first-line and second-line Line probe assays (LPA). All unexpected suspicious lung lesions depicted by imaging should be investigated or biopsied, if possible. Importantly, in addition to TB reactivation, the differential diagnosis in such situations should always include metastatic progressive disease and granulomatous sarcoid-like reactions during cancer immunotherapy.

Management and monitoring
Patients with an IGRA positive result without diagnosis of active TB could be considered for TB chemoprophylaxis before starting immunotherapy (level of evidence V,
grade of recommendation C). Data available regarding chemoprophylaxis in patients with cancer immunotherapy are scarce, and this therapeutic strategy is based on data from patients treated with anti-TNF-α antibodies. Treatment during 4 weeks with isoniazid (plus rifapentine) significantly reduces the risk of developing active TB. Most studies suggest that treatment with isoniazid (plus rifapentine) should be initiated at least 1 month before anti-TNF-α administration, although it could be initiated at any time, even concurrent with anti-TNF-α administration. When a serious immune-related adverse event occurs, delaying anti-TNF-α is not reasonable. The main concern about chemoprophylaxis in patients who must complete immunotherapy is that isoniazid is hepatotoxic and it can increase the risk of immune-related liver toxicity. Moreover, when anti-PD-1/PD-L1 therapy is used in the adjuvant setting, delaying therapy until completion of chemoprophylaxis could be reasonable. However, in the advanced setting, recommendation to delay cancer treatment must be taken with caution. The panel cannot make a formal recommendation about chemoprophylaxis during immunotherapy, and the risk of hepatotoxicity must be balanced considering the low frequency of TB reactivation reported in the literature. Chemoprophylaxis could be mainly considered for young patients before adjuvant treatment, but in patients with advanced tumors, mainly older persons, delaying immunotherapy or assuming a high risk of toxicity starting chemoprophylaxis in combination with immunotherapy is not justified (level of evidence V, grade of recommendation C). Patients who have initiated chemoprophylaxis should be monitored for clinical signs of hepatitis during TB chemoprophylaxis (level of evidence II, grade of recommendation A). In patients with hepatotoxicity due to chemoprophylaxis, chemoprophylaxis should be permanently discontinued, while immunotherapy should be reintiated when hepatotoxicity is resolved (figure 3).

In case of active TB or TB reactivation during immunotherapy, immunotherapy must be withheld due to the possibility of an exaggerated inflammatory response (level of evidence IV, grade of recommendation A). Treatment should be started with high-dose corticosteroids and combination of isoniazid, rifampicin, pyrazinamide, and ethambutol for 8 weeks, followed by isoniazid and rifampicin for 18 weeks (level of evidence II, grade of recommendation A) (figure 3). There is no evidence about the exact time for resumption of immunotherapy after initiation of anti-TB treatment or if the immunotherapy must be permanently stopped. Several factors should be considered, including the severity of TB infection, overall tumor burden, tumor control, and comorbidities. In case of adjuvant immunotherapy, completion of anti-TB therapy should be the preferred option (level of evidence IV, grade of recommendation B) (figure 3). In case of immunotherapy for advanced cancer, a short course of TB therapy of at least 2 weeks is recommended before restarting cancer immunotherapy (level of evidence V, grade of recommendation C). In case of restarting immunotherapy, close monitoring is mandatory in order to check for overlapping toxicities, especially liver toxicities (level of evidence V, grade of recommendation C) (figure 3).

SOLID TRANSPLANT RECIPIENTS

Incidence and pathophysiology

Long-term survival after solid organ transplantation has increased during the last decades. Solid organ transplant recipients (SOTRs) require lifelong immunosuppression. The required level of immunosuppression varies between different organ transplant types, with liver transplant being the one needing the lowest level. Calcineurin inhibitors, ciclosporin and tacrolimus, blocking signal 2 of T cell

---

**Figure 3** Diagram of TB screening and treatment of patient candidates for immunotherapy. IGRA, interferon gamma release assay; IO, Immunotherapy; LTBI, latent tuberculosis; PD-1, programmed cell death-1; PD-L1, programmed cell death-1 ligand; PE, physical examination; TB, tuberculosis; TST, Mantoux tuberculin skin test.
activation are the main immunosuppressive medications used in combination with agents that interact with the cell cycle, such as mycophenolate mofetil. It is unclear whether these drugs interfere with the antitumor effect of anticancer immunotherapy, but SOTRs who develop malignant tumors pose a challenge for anticancer immunotherapy because T cell stimulation is implicated as one of the major mediators of allograft rejection. The incidence of de novo malignancies, including non-melanoma skin cancer, malignant melanoma, lymphoma, kidney, head and neck cancer, colorectal cancer, and lung cancer, is high in organ transplant recipients. These patients have been excluded from clinical trials with immune checkpoint inhibitors and the benefit and risks of such treatment have not been systematically evaluated in SOTRs. Serious immune-related adverse events seem to be as common as in the general population, although they are more frequent in patients without graft rejection. The main concern in these patients is the risk of graft rejection that occurs in 37%–41% of patients, with graft loss in almost 80% of cases and death due to graft rejection in 38%–45%. Published data demonstrated no association with the length of time after organ transplantation and the risk of organ rejection. Although the rates of rejection are similar according to the different organs transplanted, analysis of case reports including data from 57 cases suggested that the rates of death secondary to graft rejection were higher in liver transplant patients (30%) than kidney (6%) or heart transplant (0%) patients.

Tumor response rate with anti-PD-1/PD-L1 or with anti-CTLA-4 antibodies varies between 25% and 40%, depending on cancer histology subtype (online supplemental table S1). According to immunosuppressant medication, patients receiving low doses of prednisone (≤10mg/day) seemed to have numerically higher tumor responses to immunotherapy with check point inhibitors therapy than those receiving mechanistic Target of Rapamycin (mTOR) inhibitors, calcineurin, or combination immunosuppressant therapy (63% compared with 42%), but in some series they also have a higher risk of graft rejection (78% vs 11%).

Although cancer during pregnancy is uncommon, when it occurs, it is not unusual that immunotherapy with anti-PD-1 antibodies is indicated, because one of the most frequent tumor during pregnancy is melanoma. In order for the fetus to not be rejected by the immune system of the mother, there is a state of immune tolerance during pregnancy. Theoretically, the inhibition of PD-1/PD-L1 or CTLA-4 during pregnancy will increase the risk of abortion and premature delivery, although three case reports in the literature have reported treatment with nivolumab, or in combination with ipilimumab, without relevant obstetric complications. These drugs probably do not increase the risk of malformations, but data on their teratogenic potential in humans are lacking.

Autoimmune disorders increase the risk of cancer development, including melanoma, so they produce a stage of chronic inflammation. One would expect that patients with autoimmune diseases would have an increased risk of immune-related adverse events in case they are treated with anti-PD-1/PD-L1 or anti-CTLA-4 antibodies. Several retrospective series
have presented data on the safety and activity of immunotherapy in patients with autoimmune disorders.49, 50 In summary, flare-ups of the pre-existing autoimmune disease were reported in 27%–50% of cases, including 10%–25% of high grade; moreover, 25%–30% of cases presented other immune-related adverse events, although a high response rate is suggested in this population.49, 50

### Management and monitoring

Previous treatment with allogeneic bone marrow transplantation is not an absolute contraindication to treatment with anti-PD-1 antibodies, and the same is true for patients previously treated with anti-PD-1 antibodies that are candidates for allogeneic bone marrow transplantation (level of evidence V, grade of recommendation A).

Pregnancy during treatment with immunotherapy must be avoided (level of evidence V, grade of recommendation A). In pregnant patients, treatment with checkpoint inhibitors is not absolutely contraindicated, although the risk of pregnancy complications is increased (level of evidence V, grade of recommendation A).

In patients with a pre-existing autoimmunity, immunotherapy is not an absolute contraindication, but every case must be individually evaluated (level of evidence V, grade of recommendation A).

### Author affiliations

1Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain
2Oncology Department, Hospital Universitari Miguel Servei, Zaragoza, Aragón, Spain
3Liver Unit, Department of Internal Medicine, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain
4Oncology Department, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain
5IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain
6Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
7Department of Infectious Diseases, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Catalunya, Spain
8Oncology Department, Hospital Germans Trias i Pujol, Badalona, Spain
9Dermatology Department, Melanoma Group IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
10Oncology Department, Azienda Ospedaliero Careggi, Firenze, Toscana, Italy
11Oncology Department, Hospital Universitario La Paz, Madrid, Spain
12Catalan Institution for Research and Advanced Studies (ICREA), Catalan Institution for Research and Advanced Studies, Barcelona, Catalunya, Spain
13Oncology Department, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
14Oncology Department, Hospital Ramon y Cajal, Madrid, Spain
15Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
16Oncology Department, ASST Papa Giovanni XXIII, Bergamo, Italy
17Oncology Department, Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain
18Department of Infectious Diseases, Hospital Universitaria de Bellvitge, Barcelona, Catalunya, Spain
19Department of Oncology, Hospital Universitario Miguel Servet, Zaragoza, Aragon, Spain
20Liver Unit, Department of Internal Medicine, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain
21Oncology Department, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain
22InstitCaixa AIDS Research Institute, Badalona, Catalunya, Spain
23Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain
24Department of Infectious Diseases, Hospital Universitari de Bellvitge, L’Hospitalet de Llobregat, Catalunya, Spain
25Oncology Department, Hospital Germans Trias i Pujol, Badalona, Spain
26Dermatology Department, Melanoma Group IDIBAPS, Hospital Clinic de Barcelona, Barcelona, Catalunya, Spain
27Oncology Department, Hospital Virgen de la Arrixaca, El Palmar, Murcia, Spain
28Oncology Department, Hospital Ramon y Cajal, Madrid, Spain
29Oncology Department, Hospital General Universitario Gregorio Marañón, Madrid, Spain
30Oncology Department, ASST Papa Giovanni XXIII, Bergamo, Italy
31Oncology Department, Consorci Hospital General Universitari de Valencia, Valencia, Comunitat Valenciana, Spain
32Department of Infectious Diseases, Hospital Universitari de Bellvitge, Barcelona, Catalunya, Spain
33Oncology Department, Hospital Universitari Miguel Servei, Zaragoza, Aragon, Spain
34Liver Unit, Department of Internal Medicine, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain
35Oncology Department, Vall d’Hebron Hospital Universitari, Barcelona, Catalunya, Spain
36IrsiCaixa AIDS Research Institute, Badalona, Catalunya, Spain
37Department of Infectious Diseases, Hospital Universitari Germans Trias i Pujol, Badalona, Catalunya, Spain

### Figure 4

Diagram of immunotherapy management of patients with previous solid organ transplants. *Consider immunotherapy for patients with cancer histologies with high chances of responding to immunotherapy and in patients with good PS and no other comorbidities. PS, performance status; SOTRs, solid organ transplant recipients.

---

**Correction notice** This paper has been updated to correct author name ‘Ivan Marquez- Rodas’.

**Twitter** Teresa Puertolas @TeresaPuertolas and Cristina Carrera @CarreraCris

**Acknowledgements** The authors thank Stephanie Davis for revision of English language.

**Contributors** MG-C had full access to all the data in the study and took responsibility for the integrity of the data and the accuracy of the analysis. Concept and design: MG-C, TP, MR, EM-C, RP, DP, EE, JM-P, IM and MM. Acquisition, analysis, or interpretation of data: MG-C, TP, MR, EM-C, RP, DP, EE, JM-P, CC, JLM, BR, JM, AB and MM. Drafting of the manuscript: MG-C, TP, MR, EM-C, RP, DP, EE, IM, JM-P and MM. Critical revision of the manuscript for important intellectual content: MG-C, TP, MR, EM-C, RP, DP, EE, JM-P, CC, JLM, BR, JM, CO, SF, BC, PC, AS, AB and MM. Obtained funding: MG-C, EE, and AB. Administrative, technical, or material support: MG-C, EE, and AB. Supervision: MG-C, EE, JM-P, IM and MM.

**Funding** This work was supported by the Spanish Melanoma Group (GEM).

**Competing interests** None declared.

**Patient consent for publication** Not required.

**Provenance and peer review** Not commissioned; externally peer reviewed.

**Open access** This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made...
indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

ORCID ids
Maria Gonzalez-Cao http://orcid.org/0000-0003-3791-540X
Ivan Marquez-Rodas http://orcid.org/0000-0002-2476-668X
Mario Mandalà http://orcid.org/0000-0001-8846-8959

REFERENCES
25 Lake AC. Hepatitis B reactivation in a long-term nonprogresor due to nivolumab therapy. AIDS 2017;31:2115–8.

Correction: Cancer immunotherapy in special challenging populations: recommendations of the advisory Committee of Spanish Melanoma Group (GEM)


This paper has been updated to correct author name 'Ivan Marquez-Rodas'.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

J Immunother Cancer 2022;10:e001664corr1. doi:10.1136/jitc-2020-001664corr1
Title: Cancer Immunotherapy in Special Challenging Populations: Recommendations of the Advisory Committee of Spanish Melanoma Group (GEM)

Maria Gonzalez-Cao1, MD; Teresa Puertolas2, MD; Mar Riveiro-Barciela3 4, MD; Eva Muñoz-Couselo5 6, MD; Carolina Ortiz5 6; Roger Paredes7 8, MD; Daniel Podzamczer9, MD; José Luis Manzano7, MD; Jose Molto7 8, MD; Boris Revollo7 8, MD; Cristina Carrera10, MD; Lourdes Mateu7 8, MD; Sara Fancelli1 11, MD; Enrique Espinosa12, MD; Bonaventura Clotet7 8, MD; Javier Martinez-Picado7 13 14 PhD; Pablo Cerezuela15, MD; Ainara Soria16, MD; Ivan Marquez-Rodas17, MD, PhD; Mario Mandala18 19, MD; Alfonso Berrocal20, MD, for the Spanish Melanoma Group (GEM).

1. Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital, Barcelona, Spain; 2. Medical Oncology Department, Hospital Universitario Miguel Servet, Zaragoza, Spain; 3. Liver Unit, Department of Internal Medicine, Hospital Universitari Vall d’Hebron, Vall d’Hebron Barcelona Hospital Campus and Universitat Autònoma de Barcelona, Barcelona, Spain; 4. Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; 5. Medical Oncology Department, Hospital Universitari Vall d’Hebron, Barcelona, Spain; 6. Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain; 7. IrsiCaixa AIDS Research Institute, Badalona, Spain; 8. Germans Trias i Pujol Research Hospital, Badalona, Spain; 9. Department of Infectious diseases, Hospital Universitari de Bellvitge, L’Hospitalet, Barcelona, Spain; 10. Dermatology Department, Melanoma Group IDIBAPS, Hospital Clinic, University of Barcelona, Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) Spain; 11. Azienda Ospedaliero-Universitaria Careggi, Firenze, Italy; 12. Hospital Universitario La Paz, Madrid, Spain; 13. Catalan Institution for Research and Advanced Studies (ICREA), Barcelona, Spain; 14. University of Vic – Central University of Catalonia (UVic-UCC. UAB), Vic, Spain; 15. Medical Oncology Department, Hospital Universitario de la Arrixaca, Murcia, Spain; 16. Medical Oncology Department, Hospital Ramon y Cajal, Madrid, Spain; 17. Medical Oncology Department, Hospital General Universitario Gregorio Marañón and CIBERONC; Madrid, Spain; 18. Melanoma Unit, Papa Giovanni XXIII Cancer center Hospital Bergamo, Italy; 19. University of Perugia, Italy; 20. Medical Oncology Department, Hospital Universitario General de Valencia, Valencia, Spain.
SUPPLEMENTARY APPENDIX
This appendix has been provided by the authors to give readers additional information about their work.

TABLE OF CONTENTS

SUPPLEMENTARY DATA: INCIDENCE AND PATHOPHYSIOLOGY..................................................3

SUPPLEMENTARY TABLES...........................................................................................................6
  Table S1.........................................................................................................................................6
  Table S2.........................................................................................................................................9

REFERENCES.............................................................................................................................11
SUPPLEMENTARY DATA: INCIDENCE AND PATHOPHYSIOLOGY

1. HIV-1 INFECTION

HIV-1 virus produces a rapid depletion of CD4+ T cells, both due to a direct cytopathic effect on infected CD4+ T cells, as well as an immune mediated effect on uninfected bystander CD4+ T cells, while CD8+ T cell counts increase due to an expansion of oligoclonal CD8+ T cells, leading to a low ratio of CD4+/CD8+ T cell counts. When patients are treated with antiretroviral drugs (ART), CD4+ T cell counts usually increase and are recovered, but in some cases, mainly if ART is initiated late in the course of the infection, CD4+ T cell counts could remain low. Moreover, patients who recover CD4+ T cell counts, can also retain high CD8+ T cell counts, leading to a low CD4+/CD8+ ratio with normal CD4+ T cell counts. The normal CD4+/CD8+ ratio in healthy persons is not fully defined, but usually it is above 1.5. In persons infected by HIV-1 a low CD4+/CD8+ ratio correlates with a stage of immune dysfunction and chronic inflammation with a higher risk of mortality.

In the prospective study conducted by Uldrick et al, inclusion of patients with less than 200 CD4+ T cells/mm³ was allowed when they had a CD4+/CD8+ ratio above 0.4.

2. VIRAL HEPATITIS

Around 30% and 95% of adults infected by HCV or HBV, respectively, will spontaneously clear the virus. Despite multiple HBV plasma markers, the most important are hepatitis B surface antigen (HBsAg), which is the marker of chronic hepatitis B infection, and the antibody against hepatitis core protein (anti-HBc), which is the marker of previous exposition to the virus. Anti-HBc antibody is positive in all HBsAg positive patients (chronic hepatitis B), but also in subjects with resolved infection (HBsAg negative with anti-HBc positive). Analysis of HBV DNA is mandatory in all HBsAg positive patients in order to assess the stage of the infection. Moreover, HBV DNA should also be carried out in HBsAg negative with anti-HBc positive cases since, although uncommon, 0.1%-2.4% of these patients have detectable HBV DNA, the so-called “occult HBV infection”, and they have an increased risk of HBV reactivation when they undergo immunosuppression (Supplementary Table 1).
3. TUBERCULOSIS INFECTION

Most TB cases are caused by Mycobacterium tuberculosis (MT). The bacillus is carried in airborne particles, called droplet nuclei, of 1–5 microns in diameter and they are generated when persons who have pulmonary or laryngeal TB disease cough, sneeze, shout, or sing. When the tubercle bacilli reach the alveoli of the lungs, they are ingested by alveolar macrophages that form a barrier shell, called granuloma. Although most of these bacilli are destroyed or inhibited, a small number of them can multiply intracellularly, and they are released when the macrophage cell dies. These bacilli may spread through the lymphatic channels or the bloodstream to more distant tissues and organs (regional lymph nodes, apex of the lung, kidneys, brain, and bones). In summary, there are three clinical situations: infection eliminated, latent TB infection (LTBI) and subclinical or active TB disease. People with LTBI cannot spread the infection to other persons. Within weeks after infection, the immune system is usually able to stop the multiplication of the bacilli, preventing further progression. Conversely, persons with TB disease are usually infectious and may spread the bacteria to others. It is caused because the tubercle bacilli overcome the immune system and multiply. Without treatment, approximately 10% of persons with a normal immune system infected by MT will develop TB disease (5% in the first or second year, and 5% later in life). Some people are at higher risk than others to develop TB disease, for example persons with non-treated HIV infection and people who are receiving immunosuppressive therapy.

People with LTBI do not have any symptoms. When TB bacilli grow in the lungs, it causes symptoms, such as: cough that lasts 3 weeks or longer, pain in the chest and coughing up blood or sputum. Other symptoms of TB disease may include: weakness or fatigue, weight loss, no appetite, chills, fever and night sweats. In 15-20% of cases, TB affects other organs, so they have additional symptoms and complications, including, meningitis, ascites, Pott’s disease (TB spondylitis), scrofula (lymphadenitis) and genitourinary alterations.

Mantoux tuberculin skin test (TST) is performed by intradermal injection of tuberculin purified protein into the inner surface of the forearm. Usually, the injection should produce a pale elevation of the skin (a wheal) 6 to 10 mm in diameter. The skin test reaction should be read between 48 and 72 hours after administration. The reaction should be measured in millimeters of the induration, but not measuring the erythema. The diameter of the indurated area should be measured across the forearm (perpendicular to the long axis).
An induration of 15 or more millimeters is considered positive in everyone. An induration of 10 or more millimeters is considered positive in recent immigrants (< 5 years) from high-prevalence countries, residents and employees of high-risk congregate settings, injection drug users, bacteriology laboratory personnel and children less than 4 years old.
### SUPPLEMENTARY TABLES

**Table S1. Summary of the main studies and reviews**

<table>
<thead>
<tr>
<th>Author</th>
<th>Condition</th>
<th>n</th>
<th>year</th>
<th>Cancer Type</th>
<th>iO</th>
<th>DCR</th>
<th>IrAEs G3-4</th>
<th>Disease reactivation</th>
<th>Study type</th>
</tr>
</thead>
<tbody>
<tr>
<td>Uldrick et al</td>
<td>HIV</td>
<td>30</td>
<td>2019</td>
<td>Anal cancer, NHL, others</td>
<td>Pembrolizumab</td>
<td>17%</td>
<td>20%</td>
<td>0</td>
<td>Prosp</td>
</tr>
<tr>
<td>Gonzalez-Cao et al</td>
<td>HIV</td>
<td>20</td>
<td>2020</td>
<td>NSCLC, melanoma, others</td>
<td>Durvalumab</td>
<td>50%</td>
<td>0%</td>
<td>0</td>
<td>Prosp</td>
</tr>
<tr>
<td>Gonzalez-Cao et al</td>
<td>HIV</td>
<td>44</td>
<td>2018</td>
<td>Melanoma, NSCLC, HCC, others</td>
<td>Nivolumab Pembrolizumab</td>
<td>25%</td>
<td>18%</td>
<td>0</td>
<td>Review of case series and case reports</td>
</tr>
<tr>
<td>Cook et al</td>
<td>HIV</td>
<td>73</td>
<td>2019</td>
<td>Melanoma, NSCLC, Kaposi, others</td>
<td>Nivolumab Pembrolizumab</td>
<td>27-63%</td>
<td>8.6%</td>
<td>7%*</td>
<td>Review of case series and case reports</td>
</tr>
<tr>
<td>Zhang et al</td>
<td>HBV</td>
<td>114</td>
<td>2019</td>
<td>HNC, nasopharyngeal, melanoma, others</td>
<td>Pembrolizumab Nivolumab Atezolizumab</td>
<td>NA</td>
<td>2%</td>
<td>5%**</td>
<td>Retrospl</td>
</tr>
<tr>
<td>Gane et al</td>
<td>HBV</td>
<td>24</td>
<td>2019</td>
<td>No cancer</td>
<td>Nivolumab</td>
<td>NA</td>
<td>0</td>
<td>90% decline viral DNA</td>
<td>Prosp</td>
</tr>
<tr>
<td>Ziogas et al</td>
<td>HBV</td>
<td>10</td>
<td>2020</td>
<td>Melanoma, NSCLC, HCC, others</td>
<td>Pembrolizumab Nivolumab</td>
<td>NA</td>
<td>NA</td>
<td>reports cases with HBV reactivation</td>
<td>Review of case series and case reports</td>
</tr>
<tr>
<td>Lee et al</td>
<td>HBV</td>
<td>60</td>
<td>2020</td>
<td>HCC</td>
<td>Pembrolizumab Nivolumab</td>
<td>3% (ir Hepatitis)</td>
<td>0/54 with NUC therapy 1/6 without NUC</td>
<td>Case series</td>
<td></td>
</tr>
<tr>
<td>Authors</td>
<td>Therapy</td>
<td>Year</td>
<td>Disease</td>
<td>Drug(s)</td>
<td>HR</td>
<td>Response</td>
<td>Complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>---------------</td>
<td>---------</td>
<td>------</td>
<td>---------</td>
<td>--------------------------</td>
<td>----</td>
<td>----------</td>
<td>-------------------------------------------------------------------------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sangro et al</td>
<td></td>
<td>2013</td>
<td>HCC</td>
<td>Tremelimumab</td>
<td>76%</td>
<td>0</td>
<td>75% decline viral RNA</td>
<td></td>
<td></td>
</tr>
<tr>
<td>El-Khoueiry et al</td>
<td></td>
<td>2017</td>
<td>HCC</td>
<td>Nivolumab</td>
<td>66%/55%</td>
<td>8%/0%</td>
<td>transient reduction</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Davar et al</td>
<td></td>
<td>2015</td>
<td>Melanoma</td>
<td>Pembrolizumab</td>
<td>50%</td>
<td>0</td>
<td>stable pVL</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Van Eeden et al</td>
<td></td>
<td>2019</td>
<td>NSCLC, melanoma, others</td>
<td>Nivolumab, Pembrolizumab</td>
<td>NA</td>
<td>NA</td>
<td>reports cases with TB reactivation</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fisher et al</td>
<td></td>
<td>2020</td>
<td>Melanoma, others</td>
<td>Nivolumab, Pembrolizumab</td>
<td>25%-60%</td>
<td>NA</td>
<td>37% Graft rejected 14% deaths due to graft rejection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Manohar et al</td>
<td></td>
<td>2020</td>
<td>Melanoma, SQCC skin, Merckel, others</td>
<td>Nivolumab, Pembrolizumab, Ipilimumab, Avelumab</td>
<td>46%</td>
<td>NA</td>
<td>41% Graft rejected 44% deaths due to graft rejection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>dzarny et al</td>
<td></td>
<td>2020</td>
<td>Melanoma, NSCLC, SQCC skin, others</td>
<td>Nivolumab, Pembrolizumab, Ipilimumab, Avelumab</td>
<td>31%</td>
<td>18%</td>
<td>40% Graft rejected 18% deaths due to graft rejection</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Burotto et al</td>
<td></td>
<td>2018</td>
<td>Melanoma</td>
<td>Ipilimumab plus Nivolumab (1st trimester)</td>
<td>PD</td>
<td>immune related Hepatitis</td>
<td>No pregnancy complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Xu et al</td>
<td></td>
<td>2019</td>
<td>Melanoma</td>
<td>Nivolumab (1st trimester)</td>
<td>CR</td>
<td>immune related Tiroiditis</td>
<td>No pregnancy complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mehta et al</td>
<td></td>
<td>2017</td>
<td>Melanoma</td>
<td>Ipilimumab plus Nivolumab (1st trimester)</td>
<td>PD</td>
<td>No irAE</td>
<td>No pregnancy complications</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Coureau et al</td>
<td></td>
<td>2020</td>
<td>Melanoma NSCLC</td>
<td>Nivolumab, Pembrolizumab</td>
<td>12%-50%</td>
<td>30%</td>
<td>27% -50% flare up of AD</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Footnotes: *Became detectable pVL **Without antiviral prophylaxis
Abbreviations: AD: autoimmune diseases; NA: no data available; NHL: non Hodgkin lymphoma; HNC: head and neck carcinoma; NSCLC: non-small cell lung cancer; Prosp: Prospective; Retrop: Retrospective; SOTR: solid organ transplant recipients; SQCC: squamous cell carcinoma; TB: tuberculosis;

<table>
<thead>
<tr>
<th>Author(s)</th>
<th>Disease</th>
<th>Year</th>
<th>Condition</th>
<th>Treatment 1</th>
<th>Treatment 2</th>
<th>Treatment 3</th>
<th>Treatment 4</th>
<th>Treatment 5</th>
<th>Treatment 6</th>
<th>Treatment 7</th>
<th>Treatment 8</th>
<th>Treatment 9</th>
<th>Treatment 10</th>
<th>Review of case series and case reports</th>
</tr>
</thead>
<tbody>
<tr>
<td>Abdel Wahab et al</td>
<td>AD</td>
<td>2018</td>
<td>Melanoma</td>
<td>Nivolumab</td>
<td>Pembrolizumab</td>
<td>Ipilimumab plus nivolumab</td>
<td>Atezolizumab</td>
<td>Others</td>
<td>NA</td>
<td>25%</td>
<td>41% flare up of AD</td>
<td>Review of case series and case reports</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Table S2. Simplified interpretation of the serological status for Hepatitis B.

<table>
<thead>
<tr>
<th></th>
<th>Anti-HBc</th>
<th>Anti-HBc IgM</th>
<th>HBsAg</th>
<th>Anti-HBs</th>
<th>HBV DNA</th>
<th>ALT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute infection</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>Detectable</td>
<td>Very increased</td>
</tr>
<tr>
<td>Chronic infection B</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>Detectable</td>
<td>Normal</td>
</tr>
<tr>
<td>Chronic hepatitis B</td>
<td>+</td>
<td>-</td>
<td>+</td>
<td>-</td>
<td>Detectable</td>
<td>Increased</td>
</tr>
<tr>
<td>Resolved hepatitis B</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>Undetectable</td>
<td>Normal</td>
</tr>
<tr>
<td>Occult hepatitis B</td>
<td>+</td>
<td>-</td>
<td>-</td>
<td>+/-</td>
<td>Detectable*</td>
<td>Normal</td>
</tr>
<tr>
<td>Vaccination</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>+</td>
<td>Undetectable</td>
<td>Normal</td>
</tr>
<tr>
<td>Not vaccinated</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Undetectable</td>
<td>Normal</td>
</tr>
<tr>
<td>neither exposed</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>-</td>
<td>Undetectable</td>
<td>Normal</td>
</tr>
</tbody>
</table>

* Usually low HBV DNA values (< 200 IU/mL).

Footnote: For the diagnosis of chronic HBV infection, several determinations in plasma or serum are used: hepatitis B surface antigen (HBs Ag), hepatitis B e antigen (HBe Ag), antibody against HBs Ag (anti-HBs), antibody against hepatitis core protein (anti-HBc) and the determination of HBV DNA by PCR. The presence of HBV DNA in serum or plasma is the gold standard for the diagnosis of the infection, as it denotes active infection and correlates with the infectivity of the patient. Nevertheless, for screening of a HBV infection, serological tests are initially indicated, and determination of viral DNA is reserved for doubtful cases. Chronic HBV infection is defined by the presence of HBs Ag in the blood for longer than six months. If negative, chronic HBV infection is typically ruled out. As Anti-HBs is a neutralizing antibody that confers protective immunity, it can be positive in previous vaccinated patients without infection and also in persons that have overcome the infection. The difference between both situations is that only persons that have been infected have detectable anti-HBc antibodies. It is very infrequent, but possible, that persons with detectable anti-HBs antibodies and HBs Ag positive are chronic carriers. The presence of HBe Ag indicates active viral replication and it does not discriminate between acute or chronic hepatitis. The presence of Anti-HBc indicates a prior exposure to the virus, but it is not a neutralizing
antibody and it does not discriminate between acute or chronic infection. In some cases, anti-HBc antibody Ig G can be the only positive marker of infection, as in the window period of acute infection, but also in some cases with chronic infection. This peculiar serological profile occurs in 1% in low-prevalence countries, but close to 20% of blood donors in countries with endemic infection. The presence of an isolated IgG anti-HBc may suggest an occult HBV infection. Occult HBV infection is currently defined as the absence of circulating HBsAg in individuals positive for HBV DNA. Usually, if anti-HBc is negative, a chronic infection can be ruled out, but in immunocompromised chronically infected patients it can be negative, although viral DNA is positive. More than 20% of the occult carriers are negative for all serum markers of HBV infection and they are called “seronegatives”.
REFERENCES

7. Diagnostic Standards and Classification of Tuberculosis in Adults and Children. This official statement of the American Thoracic Society and the Centers for Disease Control and Prevention was adopted by the ATS Board of Directors, July 1999. This statement was endorsed by the Council of the Infectious Disease Society of America, September 1999. Am J Respir Crit Care Med 2000;161:1376-95.


